In our study we propose to: 1- incorporate Docetaxel as part of the induction neoadjuvant regimen in all patients. 2- tailor the neoadjuvant chemotherapy regimen according to the preoperative response as judged by MRI so that patients whose maximum response after the first four courses of an anthracycline-docetaxel based combination, is a partial remission or less, will receive four courses of a non-cross resistant regimen. 3- prolong the duration of neoadjuvant preoperative chemotherapy to a total of eight courses. 4- complete the neoadjuvant chemotherapy before surgery so that the chances for a pathological CR are increased. 5- include Trastuzumab (Herceptin) as part of the neoadjuvant treatment in patients who are Her-2 positive.